Madrigal Pharmaceuticals company profile

MDGL · NASDAQ · USD

Compare Madrigal Pharmaceuticals
$421.99Change from previous close: −0.46%Absolute change: −$1.97

Close · November 17, 2026

Company profile

Madrigal Pharmaceuticals has 915 employees and is headquartered in West Conshohocken, United States.

Madrigal Pharmaceuticals, Inc. recorded revenue of $958.4 million in the fiscal year ended December 2025, and its work is concentrated on metabolic dysfunction-associated steatohepatitis, or MASH, a form of liver disease. The biopharmaceutical company develops novel therapeutics for this condition, with a focus on the United States market. Its main product is Rezdiffra, a liver-directed thyroid hormone receptor beta agonist used for treating MASH, which is the basis of its commercial activity.

In the same fiscal year the company posted a net loss of $288.3 million. Both figures are stated in U.S. dollars for the period ended December 31, 2025. The company had 915 employees and is headquartered in West Conshohocken, Pennsylvania.

Company facts

Industry
Biotechnology
Headquarters
1001 Conshohocken State Road, 19428, West Conshohocken
Employees
915
Chief executive
William Sibold
Founded
2011
Fiscal year
January - December
Listing
MDGL · NASDAQ
Currency
USD
ISIN
US5588681057

Madrigal Pharmaceuticals and its competitors

The most similar companies by business and size

CompanyCountryMarket capEmployeesOperating marginP/E (trailing 12 months)
Madrigal PharmaceuticalsMDGLUnited States$9.93B915-10.7%—
Corcept TherapeuticsCORTUnited States$9.36B7300.8%190.2
BioMarin PharmaceuticalBMRNUnited States$11.09B3,22116.3%146.8
Summit TherapeuticsSMMTUnited States$11.32B2650.0%—
Bio-TechneTECHUnited States$11.43B3,00021.7%66.8
Twist BioscienceTWSTUnited States$7.4B979-28.8%—

Competitors: same or related industry, same region first, then the closest market capitalization. Market cap converted into US dollars at the latest exchange rates; P/E over the last 12 months, not shown when negative.

Compare Madrigal Pharmaceuticals with its competitors